Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 11/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17939175 | 0.93 | JAK3 (0.49) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939271 | 0.93 | JAK3 (0.49) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939177 | 0.93 | JAK3 (0.49) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17938957 | 0.92 | SGK1 (0.48) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939017 | 0.91 | JAK3 (0.46) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939015 | 0.91 | JAK3 (0.46) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939484 | 0.91 | JAK3 (0.46) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939494 | 0.91 | JAK3 (0.47) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17939510 | 0.91 | PLCG1 (0.52) | JAK3NEK1NTRK1PLCG1GSK3B | |
| SCHEMBL17938842 | 0.87 | JAK3 (0.45) | JAK3PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10150783-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2016118951-A2 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | JAK3 1704/4885NEK1 58/4885NTRK1 2003/4885 |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | JAK3 1704/4885NEK1 58/4885NTRK1 2003/4885 |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | JAK3 1704/4885NEK1 58/4885NTRK1 2003/4885 |
| US-10150783-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | ITK, NFKBIA, TNNI3K | JAK3 1704/4885NEK1 58/4885NTRK1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.